Bio-Thera Solutions, Ltd. — Investor Relations & Filings
About Bio-Thera Solutions, Ltd.
Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 百奥泰 自愿披露关于BAT4406F注射液获得药物临床试验批准通知书的公告 | 2025-07-21 | Chinese | |
| 百奥泰 自愿披露关于BAT2506（戈利木单抗）注射液上市许可申请获得美国FDA受理的公告 | 2025-07-16 | Chinese | |
| 百奥泰 自愿披露关于与SteinCares就BAT2406（度普利尤单抗）注射液签署授权许可及生产、供货和商业化协议的公告 | 2025-06-23 | Chinese | |
| 百奥泰 自愿披露关于Usymro（乌司奴单抗注射液）获欧洲药品管理局人用药品委员会积极意见的公告 | 2025-06-20 | Chinese | |
| 百奥泰 关于BAT2206（乌司奴单抗）注射液获得美国FDA上市批准的公告 | 2025-05-23 | Chinese | |
| 百奥泰 关于调整BAT3306（帕博利珠单抗）开发策略的公告 | 2025-05-22 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2025
15 filings
| |||||
| 39230429 | 百奥泰 自愿披露关于BAT4406F注射液获得药物临床试验批准通知书的公告 | 2025-07-21 | Chinese | ||
| 39230423 | 百奥泰 自愿披露关于BAT2506（戈利木单抗）注射液上市许可申请获得美国FDA受理的公告 | 2025-07-16 | Chinese | ||
| 39230415 | 百奥泰 自愿披露关于与SteinCares就BAT2406（度普利尤单抗）注射液签署授权许可及生产、供货和商业化协议的公告 | 2025-06-23 | Chinese | ||
| 39230409 | 百奥泰 自愿披露关于Usymro（乌司奴单抗注射液）获欧洲药品管理局人用药品委员会积极意见的公告 | 2025-06-20 | Chinese | ||
| 39230403 | 百奥泰 关于BAT2206（乌司奴单抗）注射液获得美国FDA上市批准的公告 | 2025-05-23 | Chinese | ||
| 39230397 | 百奥泰 关于调整BAT3306（帕博利珠单抗）开发策略的公告 | 2025-05-22 | Chinese | ||
| 39230388 | 上海市方达（广州）律师事务所关于百奥泰生物制药股份有限公司2024年年度股东大会的法律意见书 | 2025-04-30 | Chinese | ||
| 39230381 | 百奥泰关于完成董事会换届选举及聘任高级管理人员和证券事务代表、内部审计负责人的公告 | 2025-04-30 | Chinese | ||
| 39230373 | 百奥泰 2024年年度股东大会决议公告 | 2025-04-30 | Chinese | ||
| 39230365 | 百奥泰 第二届监事会第二十次会议决议的公告 | 2025-04-28 | Chinese | ||
| 39230358 | 百奥泰 2025年第一季度报告 | 2025-04-28 | Chinese | ||
| 39230355 | 百奥泰 股东减持股份计划公告 | 2025-04-23 | Chinese | ||
| 39230349 | 百奥泰 关于召开2024年度科创板集体业绩说明会的公告 | 2025-04-23 | Chinese | ||
| 39230345 | 百奥泰 自愿披露关于注射用BAT7111获得药物临床试验批准通知书的公告 | 2025-04-21 | Chinese | ||
| 39230338 | 百奥泰 关于选举公司第三届董事会职工代表董事的公告 | 2025-04-18 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Bio-Thera Solutions, Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/58210/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=58210 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=58210 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=58210 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 58210}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Bio-Thera Solutions, Ltd. (id: 58210)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.